LISATA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
LISATA THERAPEUTICS, INC. (LSTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 276.68 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 264.24K shares, a 67479.80% increase year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 12.44K shares, a 31.69% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 8.19K shares, a 1179.53% increase year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 26.80K shares, a 1009.52% increase from fiscal 2024.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 2.42K shares, a 90.18% decline from fiscal 2023.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 24.60K shares, a 144.10% increase from fiscal 2022.
- LISATA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 10.08K shares, a 90.80% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 264.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 276.68K shares 10-Q · filed 2026-08-06 | 276.68K shares derived: sum of 3 quarters · filed 2026-08-06 | 284.87K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 12.44K shares 10-Q · filed 2026-05-11 | 12.44K shares derived: sum of 2 quarters · filed 2026-05-11 | 20.63K shares derived: sum of 3 quarters · filed 2026-05-11 | 21.02K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 8.19K shares derived: sum of 2 quarters · filed 2026-03-12 | 8.58K shares derived: sum of 3 quarters · filed 2026-03-12 | 26.80K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 8.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 8.58K shares derived: sum of 2 quarters · filed 2025-11-06 | 26.80K shares 10-Q · filed 2025-11-06 | 27.41K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 391.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 18.61K shares 10-Q · filed 2025-08-07 | 19.22K shares derived: sum of 3 quarters · filed 2025-08-07 | 19.86K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 18.21K shares 10-Q · filed 2025-05-08 | 18.83K shares derived: sum of 2 quarters · filed 2025-05-08 | 19.47K shares derived: sum of 3 quarters · filed 2025-05-08 | 19.47K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 612.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 1.25K shares derived: sum of 2 quarters · filed 2025-02-27 | 1.25K shares derived: sum of 3 quarters · filed 2025-02-27 | 2.42K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 640.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 640.00 shares derived: sum of 2 quarters · filed 2024-11-12 | 1.80K shares 10-Q · filed 2024-11-12 | 1.80K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 1.16K shares 10-Q · filed 2024-08-12 | 1.16K shares derived: sum of 3 quarters · filed 2024-08-12 | 23.25K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 1.16K shares 10-Q · filed 2024-05-09 | 1.16K shares derived: sum of 2 quarters · filed 2024-05-09 | 23.25K shares derived: sum of 3 quarters · filed 2024-05-09 | 23.25K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 22.08K shares derived: sum of 2 quarters · filed 2024-02-29 | 22.08K shares derived: sum of 3 quarters · filed 2024-02-29 | 24.60K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 22.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 22.08K shares derived: sum of 2 quarters · filed 2023-11-02 | 24.60K shares 10-Q · filed 2023-11-02 | 29.29K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 2.52K shares 10-Q · filed 2023-08-14 | 7.21K shares derived: sum of 3 quarters · filed 2023-08-14 | -37.06K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 2.52K shares 10-Q · filed 2023-05-09 | 7.21K shares derived: sum of 2 quarters · filed 2023-05-09 | -37.06K shares derived: sum of 3 quarters · filed 2023-05-09 | -10.68K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 4.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -39.59K shares derived: sum of 2 quarters · filed 2023-03-30 | -13.20K shares derived: sum of 3 quarters · filed 2023-03-30 | 10.08K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | -44.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -17.89K shares derived: sum of 2 quarters · filed 2022-11-10 | 5.39K shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 26.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 49.66K shares 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | 23.27K shares 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | 109.55K shares 10-K · filed 2022-03-22 | |||
| 2020-12-31 | 242.64K shares 10-K · filed 2021-02-25 | |||
| 2019-12-31 | 180.59K shares 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |